Proteinase K Market Report

To learn more about this report, Download Free Sample Report

Global Proteinase K Market Size

The global proteinase K market size was valued at USD 60.18 billion in 2025 and is anticipated to reach USD 63.73 billion in 2026 from USD 100.81 billion by 2034, growing at a CAGR of 5.90% during the forecast period from 2026 to 2034.

Proteinase K is an enzyme known as a serine protease that breaks down proteins into hydrolysis of peptide bonds. Proteinase K is a broad-spectrum protease enzyme that can digest a wide variety of proteins, including those that are resistant to other proteases. Proteinase K is widely used in the analysis of protein structure and function as it helps remove the nucleases that degrade the DNA and RNA. Proteinase K is used for sample preparation in various research and diagnostic applications as it is stable in a wide range of pH and temperature and withstands many detergents and denaturing agents. Proteinase K is prominently used in molecular biology and biochemistry applications for breaking down structural proteins and enzymes. 

MARKET DRIVERS

The rising prevalence of chronic immunogenic and hereditary diseases related to gene sequencing, DNA extraction, and others drives the market value growth for Proteinase K. The growing research regarding the innovations in cell separation methods by diagnostic labs and research laboratories is boosting the adoption of Proteinase K for DNA and RNA extraction. Proteinase K is used in the sample preparation for long-read sequencing as it completes the sample processing in 30 to 40 minutes rather than 5 to 6 hours for DNA pieces of 40kb to 50kb in length. Proteinase K has a primary role in the purification of DNA, and these techniques are expected to fuel the demand for proteinase K in the global market. According to an article published in June 2022 in the Journal of Functional Polymers, Proteinase K can be used along with the antimicrobials, enhancing antimicrobial penetration through biofilm. It enhances the ability to disperse over the biofilm of methicillin-resistant Staphylococcus aureus by inducing the entry of an antimicrobial agent. 

The increasing government initiatives for promoting genomics research are due to the growing sequencing technology. The government is funding research and development activities, fueling the growth of Proteinase K's market share. For instance, in April 2021, the government of Singapore launched the National Precision Medicine Strategy to better analyze how phenotypic, genomic, clinical factors and lifestyle affect the country's health increasing investments by the market players in R&D for seeking innovations in cell separation and sample sequencing methods. 

There are growing benefits of Proteinase K in diagnostic applications as these enzymes are associated with in vitro diagnostics. Proteinase K can be used as a supplement in molecular diagnostic applications such as NGS and PCR. Increasing demand for NGS and PCR is expected to propel the growth of demand for proteinase K. Proteinase K is used in the DNA extraction step before the PCR to improve the DNA sample quality.

To conduct the research effectively, market key players collaborate with clinic search organizations to expand their product portfolio, creating market growth opportunities during the forecast period. The growing demand for proteinase K in Point-of-Care diagnostic testing is estimated to fuel the market value growth during the forecast period. Various POC devices are developing with advanced technology, influenced by the increasing demand for proteinase K over the forecast period. 

The increasing advancements in proteomics have led to innovative applications in protein library generation for genomic studies, where proteinase K plays a crucial role in RNA and DNA purification processes. The rising prevalence of chronic diseases like cancer, cardiovascular diseases, and blood disorders influences the market expansion in the forecast period.

MARKET RESTRAINTS

The growing availability of alternative proteases and other substitutes for DNA purification is expected to hamper the market growth. Some alternatives offer better benefits compared to proteinase K, such as broad enzymatic activity and ease of inactivation, limiting the demand for proteinase K. Various advanced technologies are launched for DNA purification, which restrains the proteinase K market value. 

Another restraining factor is the availability of new alternative technologies for protein purification, where the new technologies give rapid results compared to Proteinase K. The ease of availability of these kits is one of the requirements necessary for isolating the pure DNA genome effect. Alternative products are readily available at low costs compared to Proteinase K, hindering market growth.

Proteinase K leads to autolysis at low concentrations, whereas it is stable at higher concentrations, which is a challenging factor for market expansion. Overusing proteinase K leads to the breakdown of the target sample, which results in the loss of activity. Proteinase K is well-known for its ability to inactivate DNases and RNases, which may sometimes damage the desired nucleic acid samples during extraction.

REPORT COVERAGE

SEGMENTAL ANALYSIS 

By Form Insights

The powder segment held the largest share of 54.5% in the global market in 2025 and is expected to dominate over the forecast period. The domination is due to the lyophilization techniques, where the lyophilization powder has high stability with a longer shelf-life. These advantages help in inexpensive shipping, where the lyophilization does not reduce the activity of the Proteinase K. All these powder advantages drive the market growth in this segment. 

The liquid segment is expected to increase with a significant CAGR over the forecast period due to more convenience in usage. The liquid form is a timesaver as the powder form takes time to solubilize. Liquid form is advantageous in large production batches, which is estimated to fuel the market growth during the forecast period. 

by Therapeutic Area Insights

The infectious diseases segment held the largest share of 31.5% 2025 in the global market revenue. Infectious diseases such as HIV, tuberculosis, and malaria in the low- and mid-income regions are projected to encourage the players to develop the products. For Instance, QIAGEN offers Proteinase K, isolated from the fungus Tritirachium. It isolates the DNA and RNA from the samples during viral and bacterial infection diagnosis. 

The neurology segment is estimated to have significant growth during the forecast period. Various therapies are still under development for neurology, such as enzyme replacement, small molecule therapies, gene-replacement therapies, and others, which are estimated to enhance market size growth over the forecast period. 

By Application Insights

The Purification of DNA and RNA segments dominated with the most significant market share of 58% in 2025. They maintained their domination over the forecast period due to the rising prevalence of infectious diseases across the world. Proteinase K is widely used in multi-stages to purify DNA & RNA. They are increasing chronic infectious diseases demand techniques that boost market growth. Purification of genomic DNA and RNA is common in CROs and biotechnology companies. 

The Situ Hybridization segment is expected to expand with a significant CAGR during the forecast period. Increasing the adoption rate due to essential benefits with rapid, accurate results drives market growth. 

By End-User Insights

The Contract Research Organizations segment dominates the global market with the largest market share, as many key players are collaborating with CROs to increase effectiveness in research procedures. Biotechnological companies showed a significant growth rate and are expected to grow steadily in the forecast period. The growing application of in situ hybridization in biotechnological companies is estimated to drive the market in the coming years. 

The academic institutes segment is projected to grow significantly over the forecast period. Academic institutes offer integrated services for in-vitro diagnostic clinical research. 

REGIONAL ANALYSIS 

North American region dominated the global market revenue with the most significant share of 46.2% in 2025. The region's massive demand for Proteinase K and the rising prevalence of chronic and infectious diseases drive the market revenue. During the Pandemic, the FDA issued Emergency Use Authorizations for in vitro COVID-19 laboratory tests, which fueled the market expansion. High applications of enzymes during RT-PCR for detecting SARS-CoV-2, where these developments enhance the market revenue in the region. 

Europe held the second dominant position in the global market due to its advanced healthcare infrastructure, which adopts cost-effective and efficient methods. The rising government initiatives and the establishment of prominent regional research centers are boosting market value growth. 

KEY MARKET PLAYERS

Some of the key market players include

• Merck KGaA
• QIAGEN
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd
• Abcam plc
• Agilent Technologies
• Minerva Biolabs GmbH
• Takara Bio Inc.
• Biocatalysts
• New England Biolabs

RECENT MARKET HAPPENINGS

• In May 2023, QIAGEN introduced its portfolio of high-quality enzymes as individual products for gaining industrial consumers and researchers across the globe. This step made QIAGEN a one-stop solution for all the research requirements. 
• In December 2022, Arctic Zymes Technologies announced that they upscaled the production of their proteinase. The upscaled proteinase is expected to meet the industry demand for proteinase. 
• In February 2022, Merck KGaA acquired Exelead and announced its plans to expand the company portfolio, influencing growth. 
• In April 2022, Thermo Fisher Scientific Inc. announced its collaboration with Matrix Clinical Trials to enhance its clinical research solutions and boost the market growth for decentralized trial solutions. 

MARKET SEGMENTATION

This research report on the global proteinase K market has been segmented and sub-segmented into the following categories.

By Form

• Powder Form
• Liquid Form

By Therapeutic area

• Infectious Diseases
• Diabetes
• Oncology
• Cardiology
• Neurology

By Application

• Purification of DNA & RNA
• In situ Hybridization
• Mitochondria Isolation
• Enzyme Removal

By End-User

• Contract Research Organizations (CROs)

• Academic Institutes
• Biotechnology Companies
• Diagnostic Laboratories

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa